Rx PHARMASIST.CA
The Pharmasist newsletter

Stay current in
Canadian pharmacy.

Pharmacy news, practice updates and fresh perspectives—delivered to your inbox.

Keep your practice informed

  • Canadian pharmacy news

    Follow the developments shaping the profession.

  • Prescriber updates

    Stay informed about newly licensed Ontario physicians.

  • What's new on Pharmasist

    Explore new resources, tools and learning opportunities.

Free newsletter

A useful addition to your inbox.

We'll send a confirmation link first. Privacy policy

All news Pharmasist News & insight

University of Alberta spotlights diclofenac foam; clinical evidence comes from small 2020 study

A November 16 interview describes FoamaDerm’s development and commercial use. Its linked clinical study followed 11 patients and had no randomized comparison group.

2 min read3 sources
Share LinkedIn X Facebook Email
Illustrative photo accompanying this news article
University of Alberta pharmacy and health research building in Edmonton. Photo: WinterE229 WinterforceMedia / Wikimedia Commons, Public domain. Image source
In this article & details

Article details

Published
Nov 19, 2026
Reading time
2 min read
Categories
Clinical Research, Pharmacy Business
Jurisdiction
Alberta
Sources cited
3
All news

A University of Alberta researcher is describing how a microemulsion foam developed at the university reached Canadian compounding pharmacies, while the clinical evidence linked to the product remains a small observational study.

In a November 16 Folio interview, pharmacy professor Raimar Löbenberg said his team developed FoamaDerm after questions from an insurer about drug release from compounded diclofenac products. The university’s Drug Development and Innovation Center worked on the formulation, and Löbenberg and colleagues established RS Therapeutics to commercialize it.

Foam base is already sold to pharmacies

The university describes a water-and-coconut-oil microemulsion delivered by a propellant-free foaming pump. Löbenberg said it dissolves the active ingredient without the grinding, solvents or specialized equipment used for some other compounded preparations.

Folio reports that the base is sold to pharmacies across Canada and that the company has established a North Carolina laboratory while pursuing U.S. availability. The November article is an interview about that work, rather than an announcement of a new randomized trial.

Clinical report followed 11 patients

The linked BMC Research Notes study was published in June 2020. Thirteen adults with musculoskeletal pain enrolled, and two were lost to follow-up. Among the remaining 11, nine reported a reduction of at least 50% in pain scores after two weeks using 2% diclofenac in microemulsion foam. Two reported minimal improvement.

No adverse effects were reported during the short follow-up. The study had no randomized control group, and its authors identified the small sample and observational design as limitations. Those findings do not establish comparative clinical superiority over other topical products or rule out uncommon harms.

Löbenberg’s account of improved drug release concerns formulation performance. The linked laboratory research and the small patient series answer different questions; faster release in a laboratory is not itself a large comparative clinical outcome.

The university says the team intends to continue testing the foam as a delivery option for medicines beyond diclofenac.

References

  1. U of A-developed nanotechnology product delivers topical pain relief faster for chronic conditions like arthritis — University of Alberta — Folio, November 16, 2026 interview
  2. Determination of efficacy and toxicity of diclofenac microemulsion formulation for musculoskeletal pain: an observational study — BMC Research Notes — Hoan Linh Banh and Andrew Cave, June 12, 2020; background clinical evidence, not a new trial
  3. Evaluation of a microemulsion-based gel formulation for topical drug delivery of diclofenac sodium — Journal of Pharmaceutical Investigation, Background formulation research

Rejoining the server...

Rejoin failed... trying again in seconds.

Failed to rejoin.
Please retry or reload the page.

The session has been paused by the server.

Failed to resume the session.
Please retry or reload the page.